On Tuesday, UroGen Pharma Ltd (NASDAQ: URGN) was -1.73% drop from the session before settling in for the closing price of $12.70. A 52-week range for URGN has been $10.60 – $20.70.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 13144.25%. When this article was written, the company’s average yearly earnings per share was at 2.16%. With a float of $38.20 million, this company’s outstanding shares have now reached $42.11 million.
The extent of productivity of a business whose workforce counts for 201 workers is very important to gauge.
UroGen Pharma Ltd (URGN) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward UroGen Pharma Ltd stocks. The insider ownership of UroGen Pharma Ltd is 9.30%, while institutional ownership is 97.78%. The most recent insider transaction that took place on Sep 09 ’24, was worth 11,236. In this transaction Chief Medical Officer of this company sold 859 shares at a rate of $13.08, taking the stock ownership to the 145,091 shares. Before that another transaction happened on Sep 09 ’24, when Company’s General Counsel sold 1,521 for $13.08, making the entire transaction worth $19,895. This insider now owns 25,226 shares in total.
UroGen Pharma Ltd (URGN) Performance Highlights and Predictions
Going through the last 3-months fiscal report unveiled on the 6/30/2024, it has been observed that the corporation posted -0.68 earnings per share (EPS) during the time that was better than consensus figure (set at -0.85) by 0.17. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.78 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.16% per share during the next fiscal year.
UroGen Pharma Ltd (NASDAQ: URGN) Trading Performance Indicators
You can see what UroGen Pharma Ltd (URGN) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 7.93. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 6.18.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.27, a number that is poised to hit -0.83 in the next quarter and is forecasted to reach -2.89 in one year’s time.
Technical Analysis of UroGen Pharma Ltd (URGN)
The latest stats from [UroGen Pharma Ltd, URGN] show that its last 5-days average volume of 0.48 million was inferior to 0.48 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 10.31%. Additionally, its Average True Range was 0.68.
During the past 100 days, UroGen Pharma Ltd’s (URGN) raw stochastic average was set at 18.61%, which indicates a significant increase from 11.06% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 42.63% in the past 14 days, which was lower than the 73.37% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.33, while its 200-day Moving Average is $15.10. Now, the first resistance to watch is $12.77. This is followed by the second major resistance level at $13.06. The third major resistance level sits at $13.33. If the price goes on to break the first support level at $12.20, it is likely to go to the next support level at $11.93. Assuming the price breaks the second support level, the third support level stands at $11.64.
UroGen Pharma Ltd (NASDAQ: URGN) Key Stats
There are 23,454K outstanding shares of the company, which has a market capitalization of 525.53 million. As of now, sales total 82,710 K while income totals -102,240 K. Its latest quarter income was 21,850 K while its last quarter net income were -33,400 K.
